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Background: Takayasu Arteritis is an idiopathic, chronic, large vessel vasculitis involving the aorta and its primary
branches. Few studies have been done in pediatric patients to date with the largest case series of US patients
published in 2003 consisting of only 6 patients.
Methods: A retrospective chart review was performed on all patients seen at Cleveland Clinic Children’s up until
2012 who met EULAR/PRINTO/PRES classification criteria for childhood Takayasu Arteritis.
Results: Twenty-one patients with a mean follow up of 2.3 years were studied. Weight loss, fatigue, and anorexia
were the most common presenting complaints. 57.1% of patients were hypertensive at first visit. The most
common examintation finding was diminished pulses (61.9%), followed by bruits, and then murmurs. Thoracic aorta
stenosis was the most common vascular abnormality. Seven of twenty-one patients responded well to methotrexate
and prednisone alone. Ten of twenty-one patients required an additional medication for symptom and disease
control (infliximab most commonly). About two-thirds of patients required at least one anti-hypertensive
medication. Eight of the twenty-one patients required surgical intervention for severe disease refractory to medications
(renal artery stenosis being the most common indication). Almost all patients reported symptomatic improvement after
surgical intervention. Two of the eight patients required a second surgery for return of symptoms. Disease sequelae
included arterial aneurysms, resolved heart failure, and hypertensive emergencies.
Conclusion: Our study emphasizes that constitutional symptoms coupled with objective findings of diminished
pulses, bruits, and hypertension should raise clinical suspicion for Takayasu Arteritis in pediatric patients.
Pharmacologic therapy alone can be successful in controlling disease progression, however surgery was successful
in minimizing symptoms when medical therapies failed.
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RheumatologyBackground
Takayasu Arteritis (TA) is an idiopathic, chronic, large
vessel arteritis involving the aorta and its primary
branches [1]. The pathologic course of the disease be-
gins with panarteritis in the adventitia which progresses
to the intima, eventually causing vascular narrowing,
occlusion, and later in disease, aneurismal formation
[2]. The incidence of TA in the pediatric population is* Correspondence: spaldis@ccf.org
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all age groups [3].
Few studies have been performed in pediatric TA patients
to date. An article published by Brunner et al. in 2010 sum-
marized the pertinent findings from almost all studies in
pediatric TA patients to date including 9 case series from
medical centers in Turkey, Canada, USA, South Africa,
Korea, India, and Mexico and 41 case reports representing
a total of 241 patients. The largest case series of US pa-
tients published in 2003 included only 6 patients [4].
TA typically manifests with an initial acute phase of con-
stitutional symptoms which correlate with the pathologicLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Percentage of patients who fulfilled EULAR/
PRINTO/PRES criteria for childhood Takayasu Arteritis
Criteria No & (%)
of patients
Presence of Angiographic (conventional, MRI, or CT)
Abnormalities
21/21 (100.0)
1. Decreased Peripheral Artery Pulse (s) or
Claudication of Extremities (Any visit)
16/21 (76.2)
2. Blood Pressure Difference of >10 mm Hg
between any two limbs (Based on 1st visit BP)
15/18 (83.3)
3. Bruits Over Aorta or Its Major Vessels (Any visit) 12/21 (57.1)
4. Hypertension (>95th percentile based on
presentation or 1st visit BP)
12/21 (57.1)
5. Elevated ESR (>20 mm/hr) 16/21 (76.2)
Met 1 supporting criteria 2/21 (9.5)
Met 2 supporting criteria 5/21 (23.8)
Met 3 supporting criteria 5/21 (23.8)
Met 4 supporting criteria 4/21 (19.0)
Met 5 supporting criteria 5/21 (23.8)
Supporting criteria = The criteria besides angiographic abnormalities (1–5).
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phase with symptoms of claudication and hypertension and
findings of pulselessness and bruits suggestive of arter-
ial occlusion and ischemia [5]. If diagnosis is delayed,
inflammation can progress to involve more areas of
vasculature and lead to stenosis, aneurysms, and even-
tually end-organ ischemia. Unfortunately, one-third of
children present after the acute phase and suffer effects
of tissue ischemia with a median time from symptom
onset to diagnosis of 19 months, close to four times
longer than adults [3,6,7].
Pediatric TA is largely a clinical diagnosis, currently
based on the European League Against Rheumatism
(EULAR)/Pediatric Rheumatology International Trials
Organization (PRINTO)/Pediatric Rheumatology European
Society (PRES) criteria [8].
To date, no comparative therapeutic studies have been
conducted in pediatric TA. Treatment options for TA
are broad and variations in care abound. Medical ther-
apy often starts with glucocorticoids and methotrexate
although recently other immunosuppressants and TNF
inhibitors have had reported efficacy with disease suppres-
sion. When a patient’s disease remains active or is deemed
“severe”, physicians have also employed alkylating agents
such as cyclophosphamide. Surgical interventions are used
when severe stenosis is present and threatening organ per-
fusion but minimal evidence of indications, outcomes, and
sustainability of treatment exist.
The primary aim of this study was to review the clinical
presentation of TA in a contemporary cohort of United
States children using recently validated EULAR/PRINTO/
PRES classification criteria, including the frequencies of
anatomic arterial involvement. The secondary aim was
to document treatment choices and outcomes in this
pediatric cohort.
Methods
This retrospective cohort study was approved by the
Cleveland Clinic Institutional Review Board which waived
patient consent. A search of the Cleveland Clinic (CC) elec-
tronic medical record system was performed up until 2012
to identify patients diagnosed at 18 years of age or younger
at Cleveland Clinic Children’s (a quaternary referral center)
with an International Classification of Diseases, Ninth
Revision code of Takayasu Arteritis (446.7). Of the 28
patients labeled with a diagnosis of Takayasu Arteritis,
21 of these patients fulfilled EULAR/PRINTO/PRES
criteria for childhood TA (Table 1) [8]. The initial 2006
EULARPRES criteria stated a diagnosis of childhood
TA is made when there exists evidence of angiographic
abnormalities plus the presence of at least one of the
following: decreased peripheral artery pulse (s) or
claudication of extremities, a blood pressure difference
of >10 mm Hg, bruits over the aorta or its major vessels,or hypertension (related to childhood normative data)
[9]. In 2010, these criteria were revised after reviewing
clinical features of 99 patients with TA. The revised
EULAR/PRINTO/PRES criteria stated the angiographic
findings could include either conventional MRI or CT
findings, blood pressure discrepancy could be present in
any two limbs, and hypertension was defined as systolic
or diastolic blood pressure >95th percentile for height.
Also, ESR >20 mm/hr or abnormal CRP was added as an
additional supporting criteria. With these new additions,
the study reported 100.0% sensitivity and 99.9% specificity
[8]. Patients were excluded if they were >18 years of
age at time of diagnosis (none) or did not meet the
EULAR/PRINTO/PRES criteria (7 patients).
Data collected included the patient’s age, gender, race/
ethnicity, family history of any rheumatologic conditions,
pertinent past medical history, and duration of care at
Cleveland Clinic Children’s. Clinical data collected in-
cluded date of symptom onset, presenting symptoms,
and symptoms present throughout care. Vital signs col-
lected included four extremity blood pressures, weight,
weight for age (per CDC growth charts), height, and BMI
percentile at first visit. Physical examination findings
collected included documentation of diminished pulses,
bruits, murmurs, rashes, muscle weakness, and ophthal-
mologic abnormalities. Laboratory data collected was
white blood cell count, platelet count, hemoglobin, ESR,
CRP, creatinine, albumin, and cholesterol levels at initial
presentation and last visit. Vascular study findings col-
lected included results from the following imaging mo-
dalities: vascular duplex studies, magnetic resonance
angiogram (MRA), computed tomography angiogram
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arterial location of involvement and type of lesion present.
Therapeutic data collected included medications at time
of first visit and throughout care. Indications for surgical
interventions along with type of surgery and outcomes
were reviewed and collected. Adverse events and disease
sequelae were evaluated and collected.
Data was stored in RedCap. Qualitative statistical analysis
of the data was performed using Microsoft Excel software.Results
Patient demographics
Seventy-one percent (15) of the 21 patients were female
(3.2:1 female to male ratio). Fifty-two percent of patients
were of Caucasian race. 3 patients were Hispanic, 1 patient
was from Jordan, 1 patient was African American, 1
patient was American Indian, 1 patient was Asian, and
1 patient was from Israel. Median duration of care at
CC was 1.2 years (1 day - 7.6 years) with a mean of
2.3 ± 2.5 years with 71.4% of patients having more
than one outpatient rheumatology visit at CC. The
earliest first visit date was in 2003 and eight of twelve
patients had been seen since 2011. Concomitant medical
diagnoses in TA patients included iron deficiency anemia
(n = 4), inflammatory bowel disease (n = 2), migraines
(n = 2), ADHD (n = 2), pyoderma gangrenosum (n = 1),
and thyroid papillary carcinoma (n = 1). One patient had a
history of a positive purified protein derivative (PPD) test
about 9 years prior to onset of symptoms for which he
was treated with isoniazid. None of the patients had family
members with any vasculitides. Frequency of autoimmune
disease in extended family members was 4/21 and included
celiac disease, mixed connective tissue disease, juvenile
idiopathic arthritis, and systemic lupus erythematosus.Clinical features
The median age of symptom onset was 13 years
(1.5 months - 17 years) with a mean of 11.5 ± 4.4 years.
The median time from symptom onset to diagnosis
was 6 months (1 month - 14 years) with a mean of
19.3 ± 35.4 months. All symptoms and their frequencies at
disease onset and throughout care are listed in Table 2.
Weight loss (47.6%), fatigue (38.0%), anorexia (23.8%), and
dyspnea (19.1%) were the most common presenting
complaints. Fatigue (28.6%), fever (23.8%), dyspnea (19.1%),
paresthesias (19.1%), and weight loss (19.1%) were the most
common complaints after initial diagnosis.
Of the recorded blood pressures at onset or first visit,
15 of the 18 patients had a >10 mm Hg difference in
systolic blood pressure between any two limbs, and 12
patients (57.1%) were classified as being hypertensive
with systolic blood pressures >95th percentile for age,
sex, and height (Table 1).Abnormal examination findings throughout disease were
reviewed. Thirteen of 21 (61.9%) patients had diminished
pulses on examination. Of these, 6 had diminished radial
pulse (s), 5 diminished dorsalis pedis pulse (s), 4 diminished
carotid pulse (s), 3 diminished femoral pulse (s), and 2
diminished brachial pulse (s). Bruits were heard in 12 of
21 of our patients (57.1%) as noted in Table 1. Of these,
7 had a carotid bruit on examination, 4 a renal bruit,
and 3 an aortic bruit. Pathologic sounding murmurs were
heard in 6 patients (28.6%). Two patients had muscular
weakness. Two patients had erythema nodosum. One pa-
tient had posterior vitreous detachment and degeneration
per dilated ophthalmologic examination.
Laboratory findings
Laboratory data at time of presentation and last visit
was reviewed when available. Of the ESRs reported on
our patients (n = 15) at presentation, 100% had an ele-
vated ESR with a mean of 78.6 mm/hr. Of the ESRs re-
ported at follow up (n = 16), only 37.5% of patients had
an elevated ESR. Of the 13 patients for which a pre-
senting ESR and follow up ESR were available, there
was a mean decrease in ESR of 66.7%. Only 1 patient
had an elevated creatinine; this patient had “abnormal
heterogeneous perfusion of the renal parenchyma with
pruned appearance of the intraparenchymal vessels”
on aortogram.
Vascular study findings
Table 3 lists the number of patients with a specific type
of vascular abnormality at different arterial locations.
The most common type of abnormality in our patients
was stenosis (66.2% of all lesions) followed by edema,
occlusion, and inflammation. Figure 1 illustrates the
percentage of patients with any type of vascular involve-
ment by anatomic location. The thoracic and abdom-
inal aorta were the most commonly affected locations
(52.4% each) followed by the right renal artery (47.6%)
and the left subclavian artery (47.6%). Typical MRA
and CTA findings are shown in Figure 2.
Treatment
The majority of our patients were treated with prednis-
one and methotrexate at some point in their disease
course (85.7% and 65.7%, respectively). Infliximab was
the next most commonly used medication (42.9%). Indi-
cations for adding, increasing dose of, or changing medi-
cation included new, worsening, or persistent symptoms,
new physical examination findings, elevated inflamma-
tory markers, or worsening findings on imaging studies.
Two patients required only prednisone to control signs
and symptoms related to TA. Seven of 21 (33.3%) patients
clinically responded favorably to methotrexate and prednis-
one alone. Ten of 21 patients (47.6%) required a medication






follow up care (our study)
Patients experiencing symptom at
disease presentation or throughout
care (Brunner et al. Review) [6]
(n = 21) (n = 21) (n = 160-230) (%)
Anorexia 5 (23.8) 1 (4.8) NR
Arthralgias 3 (14.3) 3 (14.3) 33/230 (14.3)
Back Pain 3 (14.3) 3 (14.3) NR
Blurred Vision 2 (9.5) 2 (9.5) NR
Carotidynia 1 (4.8) 1 (4.8) NR
Chest Pain 1 (4.8) 3 (14.3) 15/199 (7.5)
Dizziness 0 (0.0) 1 (4.8) NR
Dyspnea 4 (19.1) 4 (19.1) 49/210 (23.3)
Emesis 2 (9.5) 0 (0.0) 40/199 (20.1)
Fatigue 8 (38.0) 6 (28.6) NR
Fever 3 (14.3) 5 (23.8) 47/160 (29.4)
Headache 3 (14.3) 3 (14.3) 66/210 (31.4)
Jaw Pain 2 (9.5) 0 (0.0) NR
Lower Extremity Claudication 3 (14.3) 3 (14.3) NR
Myalgias 0 (0.0) 3 (14.3) NR
Night Sweats 3 (14.3) 1 (4.8) NR
Non- Post-Prandial Abdominal Pain 1 (4.8) 2 (9.5) 33/199 (16.6)
Palpitations 1 (4.8) 1 (4.8) 29/199 (14.6)
Paresthesias 1 (4.8) 4 (19.1) NR
Post-Prandial Abdominal Pain 1 (4.8) 2 (9.5) NR
Rash/Skin Lesions 0 (0.0) 2 (9.5) 12/230 (5.2)
Seizure-like Activity 2 (9.5) 0 (0.0) NR
Syncope 1 (4.8) 2 (9.5) 4/199 (2.0)
Upper Extremity Claudication 0 (0.0) 3 (14.3) NR
Weight Loss 10 (47.6) 4 (19.1) NR
NR = Not Reported.
Table 3 Frequency of different arterial abnormalities at specific sites in 21 children with Takayasu Arteritis
Type of abnormality AA IA LSA RSA LVA RVA LCA RCA TDA CT SMA LRA RRA AbA IMA LIF RIF PA Total
Aneursym 0 0 1 1 0 0 0 0 1 0 0 0 0 1 0 0 0 0 4
Dilation 4 1 1 0 0 0 2 0 1 0 0 0 0 0 0 0 0 0 9
Edema 2 2 0 1 0 0 1 1 3 0 0 0 0 3 0 0 0 0 13
Inflammation 2 0 0 1 0 0 1 1 3 0 0 0 0 2 0 0 0 0 10
Stenosis* 7 6 6 7 1 1 9 8 9 6 5 5 8 9 1 3 4 1 96
Occlusion 0 0 0 1 0 0 1 0 0 1 4 1 2 0 0 0 0 0 10
Plaque 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 2
Thrombus 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1
Total 15 9 8 11 1 1 15 11 17 7 10 6 10 15 1 3 4 1
*Definition for renal artery stenosis = 60% or greater on Duplex.
AA = Ascending Aorta, IA = Innominate Artery, LSA = Left Subclavian Artery, RSA = Right Subclavian Artery, LVA = Left Vertebral Artery, RVA = Right Vertebral Artery,
LCA = Left Carotid Artery, RCA = Right Carotid Artery, TDA = Thoracic Descending Aorta, CT = Celiac Trunk, SMA = Superior, Mesenteric Artery, LRA = Left Renal
Artery, RRA = Right Renal Artery, AbA = Abdominal Aorta, IMA = Inferior Mesenteric Artery, LIF = Left Iliofemoral Artery, RIF = Right Ileofemoral Artery,
PA = Pulmonary Artery.




Right Renal Artery: 47.6%
Inferior Mesenteric Artery: 4.8%
Left Subclavian Artery: 47.6%
Left Vertebral Artery: 4.8%
Thoracic Descending Aorta: 52.4%
Superior Mesenteric Artery: 42.9%
Abdominal Aorta: 52.4%
Left Iliofemoral Artery: 14.3%
Right Iliofemoral Artery: 19.0%
Left Renal Artery: 28.6%
Innominate Artery: 33.3%
Right Subclavian Artery: 42.9%
Right Vertebral Artery: 4.8%
Left Carotid Artery : 42.9%Right Carotid Artery : 38.1%
Figure 1 Prevalence of specific arterial involvement in children with Takayasu Arteritis.
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and disease control [anakinra (n = 3), cyclophosphamide
(n = 5), etanercept (n = 2), infliximab (n = 9), IV steroids
(n = 6), or mycophenolate mofetil (n = 3)]. Infliximab
was the most commonly used medication when dis-
ease activity was still present despite prednisone anda
Figure 2 Radiologic abnormalities in children with Takayasu Arteritis.
caliber and irregularity of the descending thoracic and abdominal aorta, w
inflammatory changes, notably in the proximal descending segment. Patien
which appears occluded in its mid segment with patent bypass graft arisin
7 per Table 4 with CTA showing inflammation around the aorta. c. Patient
ascending aorta, moderately dilated distal ascending aorta, and aneurysma
The largest transverse aortic arch dimension is 30 × 26 mm.methotrexate use (9/21 patients [42.9%]). The majority
of patients (14/21; 66.7%) required at least one anti-
hypertensive medication. Beta blockers were used in
almost half our patients to treat hypertension. Aspirin
was used in 38.1% of patients when the presence of
stenotic lesions warranted thrombosis prevention.b
c
a. Patient 4 per Table 4 with MRA showing significantly decreased
ith minimally increased signal characteristics, consistent with
t is status post right sided nephrtectomy with single left renal artery,
g from the mid infra-renal abdominal aorta to the left kidney. b. Patient
7 per Table 4 with MRA findings of a mildly prominent proximal
l transverse aortic arch extending into the proximal descending aorta.
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intervention while 13 were managed with medical treat-
ment alone. Table 4 summarizes surgical procedures
performed, the indication for the procedure, and post-
surgical outcomes for this cohort. The most commonly
involved vascular site requiring surgical correction was
the renal arteries (5/8 patients) while the most commonTable 4 Outcomes of children who underwent surgical interv
Patient Surgical procedure (s) Indication (s)
1 -Ross procedure -Severe aortic regu
echocardiogram; d
symptoms of heart
-Pulmonary artery stent placement -Severe pulmonary
2 -Replacement of ascending aorta, aortic arch,
and proximal descending aorta with elephant




-Abdominal aortic aneurysm resection,
infrarenal graft, and IMA revascularization
-SMA occlusion, inf
per MRA
3 -Right renal artery angioplasty -Severe hyptertensi
severe right renal a
per MRA
4 -Bilateral renal artery angioplasty -Malignant hyperte
IV anti-hypertensive
-Right nephrectomy and left kidney




5 -Renal artery angioplasty -Renal arteries and
per CTA





6 -Left renal artery stent -Severe left renal ar
per CTA; hypertens
7 -Right nephrectomy -Severe renal artery
hypertension




occlusion of the pr
subclavian artery pindication for correction of the renal arteries was hyper-
tension with evidence of severe stenosis on imaging.
These patients either underwent angioplasty, stenting,
bypass, and/or nephrectomy. The remaining three pa-
tients required surgical intervention for ascending aorta
and aortic arch involvement, 2 of which had aneurysmal





-Improvement in symptoms; mild aortic narrowing
on MRA ~6 months post-op; annulo-aortic ectasia
with enlargement of root and ascending aorta per
CTA ~2 years post op; mild aortic regurgitation on
echocardiogram ~3 years post-op
artery narrowing -No significant stenosis of the main or central
pulmonary arteries ~1 year and ~2 years post op per
CTA; diastolic flow reversal in the proximal pulmonary
artery branches suggestive of free pulmonary
insufficiency on echocardiogram ~2 years post-op
mity claudication,
of the distal arch
per MRA
-No improvement of lower extremity
claudication; stable appearance of graft
~6 months post op
rarenal stenosis -Resolution of lower extremity claudciation
~1 year post op; intact infrarenal graft, proximal
superior SMA occlusion, reimplanted inferior
mesenteric artery appears moderately narrowed
at the anastomosis on MRA ~ 1 year post op
on; headache;
rtery stenosis
-Improvement in hypertension and headaches;
right renal artery stenosis per MRA and
ultrasound ~2 months post op; widely patent




-Initial improvement of blood pressure, but




-Improved hypertension; Mild stenosis of left renal
artery 3 days post op per renal ultrasound; MRA 5
days post op with left renal artery occlusion in its
mid segment with patent bypass graft




-Further improvement of hypertension; MRA ~1
week post op with patent SMA graft with
occlusion at ostium, patent right renal artery,
patent left renal artery bypass with occlusion
at ostium; ~1 year post op CTA with patent left
renal artery bypass, mild stenosis of right renal
artery, SMA occluded but asymptomatic
tery stenosis
tion
-Improvement in hypertension; MRA ~6 months
post-op with patent bilateral renal arteries; patent
on MRA ~3 years post op





-2 days post op CTA showed intact graft; MRA ~1
year post op with stable aortic dimensions; MRA
~3 years post op with thickening to the aortic arch
and interval development of thickening and dilation
of the descending aorta; patient has remained on
infliximab since surgery
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and required renal artery bypass surgery due to return
of symptoms and/or findings on imaging. Both of these
patients had severe hypertension requiring intravenous
anti-hyptertensives. Patient 6 underwent renal artery
stenting; he was found to be asymptomatic and had
patent vasculature at follow up. Patient 7 reported
symptomatic improvement but no follow up imaging
was available. Four of the 8 patients (1, 2, 3, and 8) re-
ported resolution of symptoms but did show some return
of vascular stenosis or aneurismal change on post-op im-
aging; however, vascular changes were not severe enough
to warrant a secondary procedure. Patient 3 demonstrated
improvement in post-op renal artery stenosis after treat-
ment with methotrexate.
Disease sequelae
Four patients had findings of arterial aneurysms on
imaging. One patient suffered ophthalmologic damage.
One patient suffered symptoms of heart failure and
acute tubular necrosis just prior to receiving her Ross
procedure; these symptoms resolved following surgical
interventions. Three patients suffered from hypertensive
emergency. Two patients required admission to a PICU
for IV anti-hypertensive drips to control hypertension
prior to renal artery stenting. Steroid adverse effects were
seen in many of our patients including steroid-induced
Cushingoid features (42.9%) and decreased bone density
(3 patients). Psychological diagnoses, including anxiety
and depression, were found in 3 patients. None of our
patients to our knowledge have suffered any of the fol-
lowing potential complications of the disease: myocar-
dial infarction, stroke, or death.
Discussion
TA is a rare large vessel vasculitis and there are few
pediatric studies published to date from which to com-
pare with our study results. In our contemporary cohort
there is a female predominance similar to other studies
[6]. Also, both the mean and median ages of symptom
onset (11.5 ± 4.4 and 13 years respectively) were similar
to the data presented by Brunner in her review article
[6]. Only one of our patients had a positive PPD test,
while studies from more endemic regions have reported
rates ranging from 29% to 90% [2,10,11]. Interestingly, 1
of our patients and 2 patients in Hahn’s review of 31
patients from South Africa reported a co-diagnosis of
papillary thyroid cancer although both had been ex-
posed to total lymphoid irradiation [10]. Inflammatory
bowel disease has also been reported multiple times
(37 per Kusunoki’s literature review) in patients with TA
and also in 2 patients in our study [3,12]. This is possibly
related to a genetically-mediated increased propensity for
autoimmune-mediated disease processes.Constitutional symptoms have been reported to be
twice as common in pediatric patients compared with
adult patients [6]. While the most common symptoms
on presentation in our patients were weight loss, fatigue,
and anorexia, other series have reported headaches (31.0%),
fever (29.0%), and dyspnea (23.0%) to be the most common
symptomatic manifestations of TA in children [6]. This dis-
crepancy could be due to a smaller sample size, recall bias
of the patient, or possibly these patients being diagnosed
earlier as constitutional symptoms manifest earlier in the
disease process when there is vasculitis and not necessarily
vascular sequelae yet. Symptoms more unique to TA
such as carotidynia and claudication were not commonly
reported. This could possibly be because they are less
frequently assessed symptoms or difficult to describe for
patients. Asking about these more rare symptoms could
be a clue to diagnosis for clinicians.
Bruits were heard in 12/21 of our patients (57.1%) and
were reported in only 38/230 (16.5%) of patients in
Brunner’s review of all pediatric patients. Thirteen of
21 (61.9%) patients had diminished pulses on examination
which is in contrast with lower rates described by Brunner
et al. in which 30/230 patients (13.0%) were found to have
poor pulses anywhere; frequency reported in adults is
22.5% [6]. In our patient population, hypertension was the
most common objective clinical finding, followed by
diminished pulses, and bruits; all were seen in over half
of our patients. This is an important finding which
highlights the need for thorough and consistent clin-
ical examination including auscultation for bruits in the
child with hypertension or otherwise generic constitu-
tional complaints such as weight loss, fatigue, headaches
and dyspnea as a means to hasten diagnosis. Of the ESR
values reported on our patients, at presentation 100% had
an elevated ESR with a mean of 78.6. Although ESR is a
very non-specific marker of inflammation, it may be an
important test to aid in making an earlier diagnosis when
patients present with vague constitutional symptoms.
Repeat ESRs may be helpful to follow as a disease activ-
ity marker and its lack of normalization should prompt
further investigation.
Vascular involvement was assessed primarily by MRA
and CTA in our patients. Both can delineate stenosis,
dilation, and aneursyms, but MRA may overestimate
partial stenosis as complete occlusion [13]. Our patients
most commonly had vascular abnormalities involving
the thoracic and abdominal aorta, consistent with other
studies in pediatric patients [6,13,14]. However, in Mexico
and Turkey, pediatric patients more commonly had renal,
subclavian, and carotid involvement [11,15]. Genetics
or differences in environmental exposures or triggers may
play a part in these differences. Similar to other studies, the
most common type of lesion in our patients was stenosis
followed by occlusion and radiographic signs concerning
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of our patients while other studies have reported incidences
ranging from 41-65% [14]. Aneurysms were found in the
right and left subclavian arteries, thoracic descending aorta,
and abdominal aorta whereas other studies have shown al-
most exclusive involvement of the abdominal aorta [14].
In general, a higher percentage of our patients met the
supporting criteria per the EULAR/PRINTO/PRES clas-
sification compared to the frequencies reported in other
studies [6]. All of our patients met at least one support-
ing criteria, and five patients met all five criteria. While
not constructed to be used as a screening tool, these cri-
teria could be used to identify a select group of patients
who require additional diagnostic imaging. While symp-
toms on presentation commonly are non-specific and
cannot stand alone as diagnostic criteria, constitutional
symptoms should be a red flag to the primary care phys-
ician or pediatric rheumatologist. Although less specific
and not part of existing diagnostic criteria, from our
series there were three patients with cardiac murmurs
on examination without diminished pulses. Our data
support the added diagnostic utility of elevated ESR.
Serum cytokine measures may in the future aid in earlier
diagnosis, disease activity assessment, and treatment re-
lated decisions as IL-18 and IL-6 have been reported to
be higher in adults with TA [18].
There is limited data regarding treatment efficacy
outcomes for children with TA. In the adult population,
about 60% of patients respond to glucocorticoids alone.
This is very different from our findings; only 2 of our
patients responded to steroids. This could be due to a
more inherently severe disease course in the pediatric
population, delayed diagnosis in the pediatric population,
or the reluctance of providers treating pediatric onset
patients to use systemic corticosteroids as a sole main-
tenance medication [6]. Studies have shown glucocortic-
oid therapy alone can consistently induce remission, but
time in remission is shortened [3]. Most of our patients
who did not respond to steroids and methotrexate were
started on infliximab. Severely ill patients were treated
with cyclophosphamide. In a limited series of 6 patients,
Ozen has shown induction with cyclophosphamide and
steroids followed by methotrexate is an effective regi-
men for pediatric patients with widespread disease [19].
Cyclophosphamide is used sparingly in the adult popu-
lation due to its potential teratogenic effects so data is
limited; however, it may be of great therapeutic use in
the pediatric population.
Antiplatelet therapy has also been hypothesized to be
beneficial in patients with TA [20]. Plasma levels of
markers of thrombosis includingplatelet factor 4, beta-
thromboglobulin, thrombin-anti-thrombin III, fibrino-
peptide A, and D-dimer are substantially higher in TA
patients [21]. This is important since inflammationcauses platelet, leukocyte, and endothelial cell activation
which leads to a hypercoaguable state [20]. Additionally,
many TA patients are on steroids which can have adverse
effects on hyperlipidemia, obesity, and hypertension, further
increasing the risk of acute ischemic events. In theory,
treatment of the underlying inflammation and selection
of an effective steroid-sparing or steroid-limiting agent
should help alleviate this risk. However, levels of these
pro-thrombotic markers have not been different be-
tween the active and inactive stages of the disease
[20,21]. This suggests treatment with anti-platelet medi-
cations such as aspirin, used in 38% of our patients, is
prudent. Adult TA patients prescribed anti-platelet
medications have shown a decreased incidence of acute
ischemic events [22].
Similar to other studies, surgical correction of renal
artery stenosis was the most common indication for
surgical intervention in our patients [15]. Almost all of
our patients reported symptomatic improvement after
surgical intervention. Other pediatric studies have shown
successful rates of PTA ranging from 83-93% [23,24]. Surgi-
cal treatment of any kind was successful in 10 of 12 patients
in another study [25]. A 20 year longitudinal study has
shown restenosis rates of 18% 5 years after surgery, 5%
between the 6th and 10th post-operative years, and 10%
between the 11th and 20th years [26]. Reddy et al. re-
ported significant restonsis requiring a second surgery
in 20% of patients [25]. Numan’s study suggests stenosis
is more likely to recur if patients had greater than 20%
stenosis preoperatively and long eccentric lesions. Both
of our patients who required a second procedure for
renal artery stenosis underwent their second surgery within
weeks of their first procedure. Of note, serial angiographic
studies have shown that new lesions can be found in 61%
of post-surgical patients without symptomatic manifesta-
tions [3]. For this reason, routine surveillance is favored to
ensure patients are receiving proper medicinal treatment at
the onset of new lesions which may prevent the need for
surgical interventions. Of note many of our patients with
symptomatic improvement post-operatively, developed new
lesions found on routine follow up imaging.
No patients died in our study, but the longest duration of
follow up was only 8 years. Hahn’s South African Study
reported a mortality rate of 22% over 15 years, while the
highest mortality rate reported in the recent pediatric
literature has been 35% over a 5 year period [11]. These
pediatric TA patients were treated solely with glucocor-
ticoids and surgical interventions, suggesting that the
use of disease modifying and biologic medications such
as methotrexate and infliximab are associated with a
decreased rate of mortality [11].
Our study is limited in that it is a retrospective chart
analysis of a cohort of children presenting to a quartern-
ary referral center. As such, most of the patients in our
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disease onset was sometimes limited if prior medical
records were not available for review. Additionally,
some patients were not seen on a regular basis at our
facility, limiting longitudinal data acquisition. Lastly,
all of our patients were adolescents at time of first visit,
further limiting the duration of care by a pediatric
rheumatologist.
Conclusion
In conclusion, our study emphasizes the finding that
constitutional symptoms as presenting complaints and
examination findings of diminished pulses, bruits, and
hypertension should raise clinical suspicion for TA.
Medical treatment alone can be successful in controlling
disease progression, however surgical interventions are
successful in eliminating symptoms when medical therapies
fail. Further research should be aimed at developing earlier,
more specific markers of disease, conducting prospect-
ive, randomized controlled studies comparing different
therapeutic regimens, and larger, long-term, observational
studies examining post-surgical outcomes to improve the
outcomes for children with this rare and potentially life
threatening disease.
Abbreviations
TA: Takayasu Arteritis; CC: Cleveland Clinic; EULAR: European League Against
Rheumatism; PRINTO: Pediatric Rheumatology International Trials
Organization; PRES: Pediatric Rheumatology European Society;
MRA: Magnetic resonance angiogram; CTA: Computed tomography
angiogram.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors contributed extensively to the work presented in this paper. HS
contributed to the study design, data acquisition and analysis, and
manuscript drafting and revisions. AZ assisted with data interpretation and
provided critical manuscript revisions. SS contributed to the conception and
design of the study, data analysis, and manuscript drafting and revisions. All
authors read and approved the final manuscript.
Acknowledgment
The authors would like to thank Dr. Unni Udayasankar for helping provide
and interpret radiographic images and Dr. Didem Buyuktas Aytac for her
assistance with the paper.
Author details
1Cleveland Clinic Children’s, Cleveland, Ohio, USA. 2Center for Pediatric
Rheumatology, Cleveland Clinic Children’s, Cleveland, Ohio, USA. 3Center of
Pediatric Rheumatology, Center for Pediatric Rheumatology, Cleveland Clinic
Children’s, 9500 Euclid Avenue/Desk A111, Cleveland, OH 44195, USA.
Received: 24 November 2013 Accepted: 18 April 2014
Published: 4 June 2014
References
1. Tullus K, Marks SD: Vasculitis in children and adolescents: clinical
presentation, etiopathogenesis, and treatment. Paediatr Drugs 2009,
11(6):375–380.
2. Jain S, Sharma N, Singh S, Bali HK, Kumar L, Sharma BK: Takayasu arteritis in
children and young Indians. Int J Cardiol 2000, 75(Suppl 1):S153–S157.3. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman
G: Takayasu arteritis. Ann Intern Med 1994, 120(11):919–929.
4. Fieldston E, Albert D, Finkel T: Hypertension and elevated ESR as
diagnostic features of takayasu arteritis in children. J Clin Rheumatol 2003,
9(3):156–163.
5. Ishikawa K: Patterns of symptoms and prognosis in occlusive
thromboaortopathy (takayasu’s disease). J Am Coll Cardiol 1986, 8(5):1041–1046.
6. Brunner J, Feldman BM, Tyrrell PN, Kuemmerle-Deschner JB, Zimmerhackl
LB, Gassner I, Benseler SM: Takayasu arteritis in children and adolescents.
Rheumatology (Oxford) 2010, 49(10):1806–1814.
7. Johnston SL, Lock RJ, Gompels MM: Takayasu arteritis: a review. J Clin
Pathol 2002, 55(7):481–486.
8. Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni
A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA,
Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN,
Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, Al-Mayouf
S, Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M, et al: EULAR/
PRINTO/PRES criteria for henoch-schonlein purpura, childhood polyarteritis
nodosa, childhood wegener granulomatosis and childhood takayasu
arteritis: Ankara 2008. part II: Final classification criteria. Ann Rheum
Dis 2010, 69(5):798–806.
9. Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, Kawasaki T,
Lindsley C, Petty RE, Prieur AM, Ravelli A, Woo P: EULAR/PReS endorsed
consensus criteria for the classification of childhood vasculitides.
Ann Rheum Dis 2006, 65(7):936–941.
10. Hahn D, Thomson PD, Kala U, Beale PG, Levin SE: A review of takayasu’s
arteritis in children in Gauteng, South Africa. Pediatr Nephrol 1998,
12(8):668–675.
11. Morales E, Pineda C, Martinez-Lavin M: Takayasu’s arteritis in children.
J Rheumatol 1991, 18(7):1081–1084.
12. Kusunoki R, Ishihara S, Sato M, Yoshiko S, Yoshiyuki M, Mayumi O, Yasumasa
T, Akihiko O, Nobuhiko F, Naoki O, Ichiro M, Takafumi Y, Shuichi S, Yuji A,
Yohko M, Yoshikazu K: Rare case of takayasu’s arteritis associated with
crohn’s disease. Intern Med 2011, 50(15):1581–1585.
13. Stanley P, Roebuck D, Barboza A: Takayusu’s arteritis in children. Tech Vasc
Interv Radiol 2003, 6(4):158–168.
14. McCulloch M, Andronikou S, Goddard E, Sinclair P, Lawrenson J,
Mandelstam S, Beningfield SJ, Millar AJW: Angiographic features of 26
children with takayasu’s arteritis. Pediatr Radiol 2003, 33(4):230–235.
15. Cakar N, Yalcinkaya F, Duzova A, Caliskan S, Sirin A, Oner A, Baskin E, Bek K,
Soylu A, Fitoz S, Bayazit AK, Bircan Z, Ozen S, Uncu N, Ekim M: Takayasu
arteritis in children. J Rheumatol 2008, 35(5):913–919.
16. Hong CY, Yun YS, Choi JY, Sul JH, Lee KS, Cha SH, Hong YM, Lee HJ, Hong
YJ, Sohn KC: Takayasu arteritis in korean children: clinical report of
seventy cases. Heart Vessels Suppl 1992, 7:91–96.
17. Jain S, Kumari S, Ganguly NK, Sharma BK: Current status of Takayasu
Arteritis in India. Int J Cardiol 1996, 54(Suppl):S111–S116.
18. Park MC, Lee SW, Park YB, Lee SK: Serum cytokine profiles and their
correlations with disease activity in Takayasu’s Arteritis. Rheumatology
(Oxford) 2006, 45(5):545–548.
19. Ozen S, Duzova A, Bakkaloglu A, Bilgner Y, Cil BE, Demircin M, Davin JC,
Bakkaloglu M: Takayasu arteritis in children: preliminary experience with
cyclophosphamide induction and corticosteroids followed by
methotrexate. J Pediatr 2007, 150(1):72–76.
20. Aksu K, Donmez A, Keser G: Inflammation-induced thrombosis:
mechanisms, disease associations and management. Curr Pharm Des
2012, 18(11):1478–1493.
21. Akazawa H, Ikeda U, Yamamoto K, Kuroda T, Shimada K: Hypercoagulable
state in patients with takayasu’s arteritis. Thromb Haemost 1996,
75(5):712–716.
22. de Souza AW, Machado NP, Pereira VM, Arraes AED, Neto ETR, Mariz HA,
Sato EI: Antiplatelet therapy for the prevention of arterial ischemic
events in Takayasu Arteritis. Circ J 2010, 74(6):1236–1241.
23. Numan F, Hasanefendioglu Bayrak A, Cantasdemir M, Ozer H, Gulsen F:
Percutaneous transluminal angioplasty in pediatric patients with
Takayasu Arteritis: Comparison of initial and long- term results of
interventions on aorta and non-aortic vessels. Anadolu Kardiyol Derg 2010,
10(3):281–284.
24. Tyagi S, Khan AA, Kaul UA, Arora R: Percutaneous transluminal angioplasty
for stenosis of the aorta due to aortic arteritis in children. Pediatr Cardiol
1999, 20(6):404–410.
Szugye et al. Pediatric Rheumatology 2014, 12:21 Page 10 of 10
http://www.ped-rheum.com/content/12/1/2125. Reddy E, Robbs JV: Surgical management of takayasu’s arteritis in
children and adolescents. Cardiovasc J Afr 2007, 18(6):393–396.
26. Kalangos A, Christenson JT, Cikirikcioglu M, Vala D, Buerge A, Simonet F,
Didier D, Beghetti M, Jaeggi E: Long-term outcome after surgical
intervention and interventional procedures for the management of
takayasu’s arteritis in children. J Thorac Cardiovasc Surg 2006,
132(3):656–664.
doi:10.1186/1546-0096-12-21
Cite this article as: Szugye et al.: Takayasu Arteritis in the pediatric
population: a contemporary United States-Based Single Center Cohort.
Pediatric Rheumatology 2014 12:21.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
